Hypertriglyceridemia Induced Acute Pancreatitis study: Evolocumab
Official title Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis
ClinicalTrials.gov ID: NCT07388420
What this study is testing
What is Evolocumab 140 mg/mL (Repatha)?
An investigational once‑every‑two‑weeks injectable medicine being studied for lowering triglycerides in hypertriglyceridemia‑induced acute pancreatitis. It is designed to inhibit PCSK9, thereby increasing LDL‑receptor recycling and reducing circulating lipids.
Also referred to as Repatha.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to see if giving evolocumab, a drug that lowers fat in the blood, helps reduce triglyceride levels and is safe for patients with hypertriglyceridemia‑induced acute pancreatitis.
- Who it's for
- Adults who have had an episode of acute pancreatitis caused by very high triglyceride levels.
- What's involved
- Participants will receive the usual lipid‑lowering treatment plus evolocumab. They will have regular clinic visits and blood tests to monitor triglyceride levels and any side effects.
- Time commitment
- The trial lasts until the patient’s triglyceride level falls below 5.65 mmol/L, with follow‑up visits every few weeks to check safety and effectiveness.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Age 18\~75 years
- Patients with HTG-AP
- Mixed hyperlipidemia
- Sign the informed consent form
You likely can't join if
- Patients who have received lipid-lowering drugs or blood purification treatment within one week before enrollment
- Patients who have used evolocumab within one month before enrollment
- Patients who are accompanied by diseases that can seriously affect the survival
- Patients who have participated in the clinical research of other drugs within one month
- Patients who are pregnant or breastfeeding
- Patients with allergic asthma, allergic urticaria, eczema, and those who have a clear history of multiple drug and food allergies
See the full eligibility criteria
- Age 18\~75 years
- Patients with HTG-AP
- Mixed hyperlipidemia
- Sign the informed consent form
- Patients who have received lipid-lowering drugs or blood purification treatment within one week before enrollment
- Patients who have used evolocumab within one month before enrollment
- Patients who are accompanied by diseases that can seriously affect the survival
- Patients who have participated in the clinical research of other drugs within one month
- Patients who are pregnant or breastfeeding
- Patients with allergic asthma, allergic urticaria, eczema, and those who have a clear history of multiple drug and food allergies
- Other circumstances that researchers consider not suitable for participation in this study
The study team makes the final eligibility decision.
Where it is enrolling
- Shenyang, Liaoning, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Shenyang, Liaoning, China. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.